AI in Medicine — Cancer & Rare Disease — 2026-10-01 (Thu) Morning News

Latest news on AI and cancer treatment

Overview

- The areas where notable movements were in the areas of diagnosis/imaging (expanded introduction of breast cancer screening AI, radiology AI) and regulations (increase in the number of approvals for radiology AI). - Regarding drug discovery and treatment selection, the headlines were about tumor drug response prediction models and funding for drug discovery AI companies. - Specific numbers indicating clinical efficacy cannot be gleaned from the headline.

Breast cancer

- Lunit expands AI breast cancer screening in Stockholm region (BioPharma APAC). The introduction is being expanded for medical examinations, and accuracy and detection rates are not in the headlines. The stage of evidence is unknown. - Article covering AI advances in breast cancer detection (Florida Weekly). The content is unclear from the headline. - The MHRA registration (scanx.trade) of Lords Mark's dialysis AI system is not applicable as it is not in the cancer field.

lung cancer

No applicable information

Malignant brain tumor

No applicable information (The article on BAG Ventures' $11.3M fund is about corporate AI investment, and the link to brain tumors cannot be read from the headline, so it is not included.)

Leukemia/lymphoma

No applicable information

Colon cancer/digestive organ

- Mayo Clinic's AI reportedly detected pancreatic cancer years before diagnosis (an item in Medical Economics' morning summary). Detection sensitivity, number of subjects, study design (retrospective or prospective, etc.) are not mentioned in the headline, and the level of evidence is unknown. - No information regarding endoscopic detection.

Rare cancer

- Global Genes joins ARPA-H funding coalition. Aiming to build the world's largest data resource for rare disease AI (PR Newswire). It is unclear from the headline whether the project is aimed at rare diseases in general, or specifically cancer (adenoid cystic carcinoma, sarcoma, etc.). There are no clinical results available at the data infrastructure construction stage. - EliseAI's fundraising with a valuation of $4 billion (Health Tech World) is not eligible because the link to cancer cannot be read from the headline.

Diagnosis/Pathology/Image

- It was reported that the number of radiology AI approvals has increased by 42%, indicating a changing regulatory environment (Radiology Business). The authorizing entity (FDA, etc.) and comparison period are not listed in the heading. - AI tool to discover and correct training gaps for radiology residents (PR Newswire). This is an educational tool, and its diagnostic accuracy performance is not listed in the headline. - Article addressing the impact of AI in radiology (WBUR). - Market research predicts that the market for medical image analysis software will reach $6.3 billion in 2031, with a CAGR of 8.5% (Wissen Research, PR Newswire). Market predictions, not clinical evidence. - Review of the impact of AI in oncology on clinical trials, workflows, and outcomes (CancerNetwork). - Post about participating in a panel on AI and cancer detection at the NFCR Global Summit (oncodaily.com).

Treatment selection/drug discovery

- An AI model that predicts a tumor's drug response by referring to "similar cells" (Bioengineer.org). The development stage and verification scale are not listed in the headline, and the stage is unknown. - AI-driven analysis and data mining strategies for drug discovery (Newswise). The content is unclear from the headline. - Rakovina Therapeutics raises funds for AI-driven cancer drug discovery program in private placement (kalkine.ca). The stage of development is unclear from the headline. This is a matter of fundraising, not an indication of effectiveness.

Regulations/Approval

- 42% increase in radiology AI approvals (Radiology Business). It is not possible to determine from the heading whether FDA, EMA, or PMDA approval is given. The item name is unknown, and it is not possible to confirm whether it is approved, designated, or under guidelines. - The MHRA's registration of the dialysis AI system (scanx.trade) is for reference only as it is outside the cancer field and is not a designated regulatory authority.

Clinical trial implementation status

Because this input does not include data from ClinicalTrials.gov, the study name, target cancer type, phase, and registration status cannot be listed (the number and status of cases cannot be estimated either).

Japanese movements

No applicable information

Remarks from VIPs

The list of important people being tracked is empty. For reference, David A. Hall (title unknown from the headline) has announced his participation on the AI and Cancer Detection Panel at the NFCR Global Summit (oncodaily.com). The content of the statement is not in the headline.

Latest news on AI and rare and intractable diseases

Overview

The most notable developments were the development of data for diagnosis and analysis infrastructure (data resources for rare disease AI, whole genome infrastructure), and reports regarding the establishment of Anthropic's biological experiment facility (drug discovery). The headings on the system side (Medical Expense Subsidy, Intractable Disease Act, Research Team) do not directly relate to Japan's designated intractable disease system. The headlines are mostly company announcements and news reports, and do not include numbers showing clinical efficacy.

Diagnosis of rare diseases

- Global Genes has joined the ARPA-H-funded consortium. It is said to be an initiative aimed at building the world's largest data resource for rare disease AI (PR Newswire). - The headline does not include figures on shortening the time to diagnosis or diagnosis rate. The evidence stage cannot be evaluated and is limited to the announcement of a plan to build a data infrastructure. - No specific disease name is indicated, and correspondence with designated intractable diseases cannot be confirmed.

Gene analysis/genome

- Tempus AI announces whole genome platform. Another heading on simplywall.st says "100,000 genomes," but the numbers don't match. You can't tell from the headline which one is correct. - Precure, LLC selects Helix as multi-omics laboratory and AI tool provider (Mayo Clinic News Network). - All of these are announcements of infrastructure development and alliances, and there are no headlines indicating the accuracy of mutation interpretation or what was determined.

Development of therapeutic drugs

- NIH reportedly supports AlphaRose's AI-designed therapeutics. The target is Bain syndrome, an ultra-rare disease (Dealroom). The only stage that can be seen from the headline is ``NIH support,'' but it is not possible to confirm whether it is preclinical or clinical. It is not possible to confirm whether Bain syndrome is a designated intractable disease. Treated as a rare disease rather than a designated intractable disease. - The Applied Clinical Trials heading includes gene therapy for pediatric diseases. The disease name and stage are unclear from the headline. - A headline on oncodaily.com talks about using AI to standardize cell and gene therapy trial matching. The topic is related to the selection of subjects for clinical trials, not the content that shows efficacy. - Regarding Anthropic, Reuters and CHOSUNBIZ reported that the company is establishing a biology lab and expanding its AI drug discovery program. The CHOSUNBIZ headline states that the company will focus on preclinical research for rare diseases. The stage is preclinical, and there are no specific diseases or outcomes in the headlines.

Nerve/muscular diseases

- CBS News reported that a brain chip and AI program are helping ALS patients communicate again. ALS (amyotrophic lateral sclerosis) is included in the list of designated intractable diseases. However, the notification number will not be given because it is not listed in the list. - The headline does not indicate the number of cases or facilities. This is a report on an individual patient, and cannot be considered evidence beyond the level of a case report. The results cannot be generalized. - The Huntington ISD headline is an article about guidelines for the use of AI in schools, and appears to be unrelated to Huntington's disease (presumably a place/school district name). Not covered by this report.

Immunology/Collagen disease

No applicable information

Rare metabolic/endocrine diseases

No applicable information

System/Patient Support

No relevant information (Global Genes is participating in the movement of patient groups, but the topic is data infrastructure and not related to medical expense subsidies or the Intractable Diseases Act)

Japanese movements

- The Nihon Keizai Shimbun reported that American company Anthropic will set up a biological laboratory facility and utilize AI for drug discovery. BigGo Finance reported that the company will secretly establish a wet laboratory, and AI drug discovery will move from simulation to actual experimentation. - All of these are domestic reports on trends in overseas companies, and there are no headlines indicating efforts by domestic research groups or institutions.

Remarks from VIPs

No relevant information (the list of important people being tracked is empty and the headline does not include any statements)